What High-Quality Reviews Say About Cannabis for Pain and Palliative Care
A review of 11 systematic reviews found limited evidence supporting THC/CBD spray for neuropathic pain and inadequate evidence for cannabinoids treating cancer pain, rheumatic pain, or anorexia.
Quick Facts
What This Study Found
This systematic review of systematic reviews examined the highest-quality evidence available on cannabinoids for pain management and palliative medicine.
Of 750 publications identified, 11 systematic reviews met inclusion criteria. Three were high methodological quality and eight were moderate. The strongest finding was limited evidence supporting THC/CBD spray for neuropathic pain.
For cancer pain, rheumatic pain, gastrointestinal pain, and anorexia in cancer or AIDS, the evidence for any cannabinoid (dronabinol, nabilone, medical cannabis, or THC/CBD spray) was inadequate.
The reviewers highlighted a significant gap between public perception and scientific evidence: the public views cannabis-based medicines as effective and safe for pain, but the systematic evidence does not support this perception. Treatment with cannabis-based medicines was associated with central nervous system and psychiatric side effects.
Key Numbers
750 publications identified; 11 systematic reviews met inclusion criteria (3 high quality, 8 moderate quality). 2 long-term observational studies with medical cannabis and 1 with THC/CBD spray were also analyzed.
How They Did This
Systematic review of systematic reviews of RCTs and prospective observational studies, searching the Cochrane Database, Database of Abstracts of Reviews of Effects, and Medline from January 2009 to January 2017. Methodological quality was assessed using the AMSTAR instrument.
Why This Research Matters
This is one of the most rigorous assessments of cannabinoids for pain, reviewing reviews rather than individual studies. The clear gap it identifies between public perception and scientific evidence has direct implications for clinical practice and patient expectations.
The Bigger Picture
This umbrella review illustrates a recurring pattern in cannabinoid research: promising preclinical results and patient reports that do not consistently translate to rigorous clinical evidence. It suggests the field needs larger, better-designed RCTs before cannabinoids can be confidently recommended for pain conditions.
What This Study Doesn't Tell Us
The search period ended January 2017 and newer evidence may have emerged. The review focused on systematic reviews, meaning individual high-quality studies not yet included in a systematic review would be missed. The included reviews varied in their definitions of pain conditions and cannabinoid formulations.
Questions This Raises
- ?Could specific cannabinoid formulations or delivery methods show stronger evidence in more targeted trials?
- ?Does the limited evidence for neuropathic pain represent a genuinely different mechanism than cancer or rheumatic pain?
- ?Would longer-term studies change the evidence picture?
Trust & Context
- Key Stat:
- 750 publications screened; only limited evidence for neuropathic pain, inadequate for cancer and rheumatic pain
- Evidence Grade:
- Systematic review of systematic reviews using validated quality assessment (AMSTAR), representing the highest tier of evidence synthesis.
- Study Age:
- Published in 2017, covering systematic reviews from January 2009 to January 2017.
- Original Title:
- Cannabinoids in Pain Management and Palliative Medicine.
- Published In:
- Deutsches Arzteblatt international, 114(38), 627-634 (2017)
- Authors:
- Häuser, Winfried(13), Fitzcharles, Mary-Ann(14), Radbruch, Lukas(4), Petzke, Frank
- Database ID:
- RTHC-01397
Evidence Hierarchy
Analyzes all available research on a topic using a structured method.
What do these levels mean? →Frequently Asked Questions
Does cannabis work for chronic pain?
This umbrella review found limited evidence that THC/CBD spray helps neuropathic pain specifically. For other types of chronic pain including cancer pain and rheumatic pain, the evidence was inadequate to support a benefit.
Is public perception of cannabis for pain accurate?
The reviewers concluded that public perception of cannabis as effective and safe for pain conflicts with what systematic evidence shows. The gap between perception and evidence is significant.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-01397APA
Häuser, Winfried; Fitzcharles, Mary-Ann; Radbruch, Lukas; Petzke, Frank. (2017). Cannabinoids in Pain Management and Palliative Medicine.. Deutsches Arzteblatt international, 114(38), 627-634. https://doi.org/10.3238/arztebl.2017.0627
MLA
Häuser, Winfried, et al. "Cannabinoids in Pain Management and Palliative Medicine.." Deutsches Arzteblatt international, 2017. https://doi.org/10.3238/arztebl.2017.0627
RethinkTHC
RethinkTHC Research Database. "Cannabinoids in Pain Management and Palliative Medicine." RTHC-01397. Retrieved from https://rethinkthc.com/research/hauser-2017-cannabinoids-in-pain-management
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.